Effect of different antiplatelet therapies on platelet function in acute coronary syndrome patients with clopidogrel resistance
Xu Xiaoyu
Shi Xiujin
Peng Wenxing
Lin Yang
Abstract：Objective To analyze antiplatelet therapies with ticagrelor and cilostazol on platelet aggregation rate in acute coronary syndrome (ACS) patients with clopidogrel resistance.Methods A total of 86 ACS patients with clopidogrel resistance (platelet aggregation rate ＞ 50％) were retrospectively enrolled from November 2007 to March 2016 in Beijing Anzhen Hospital,Capital Medical University.The patients used to have antiplatelet therapy with aspirin and clopidogrel;64 cases of them had ticagrelor replacing clopidogrel;22 cases were added cilostazol.Platelet aggregation rate was analyzed.Results The platelet aggregation rate in ticagrelor group was significantly lower than that in cilostazol group[(24 ± 11) ％ vs (26 ± 28) ％] (P ＜ 0.01).The decline rate and the standard-reaching rate of platelet aggregation rate in ticagrelor group were significantly higher than those in cilostazol group [67.12％(50.41％,75.47％) vs28.15％(8.41％,50.51％),96.9％ (62/64) vs63.6％(14/22)](P＜ 0.01).Conclusion Clopidogrel resistance patients with high bleeding risk can use cilostazol in combination with aspirin and clopidogrel;patients with low bleeding risk can use aspirin and ticagrelor.
Keywords：Acute coronary syndromeClopidogrel resistanceCilostazolTicagrelorPlatelet aggregation rate
Publication Date：2017-04-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 496-499 )